METERED AEROSOL DISPENSING APPARATUS AND METHOD OF USE THEREOF
    12.
    发明申请
    METERED AEROSOL DISPENSING APPARATUS AND METHOD OF USE THEREOF 审中-公开
    计量气溶胶分配装置及其使用方法

    公开(公告)号:WO1995012533A1

    公开(公告)日:1995-05-11

    申请号:PCT/US1994012551

    申请日:1994-11-01

    Inventor: GLAXO INC.

    CPC classification number: B65D83/54

    Abstract: The present invention relates to an aerosol dispensing apparatus (1), more particularly to aerosol dispensing valves incorporating a controlled metered dispensing function wherein the metering chamber (7) holding the next aerosolized dose is in fluidic communication with the reservoir (3) allowing homogenous mixing of the next aerosolized dose to be dispensed.

    Abstract translation: 气雾剂分配装置技术领域本发明涉及一种气溶胶分配装置(1),更具体地涉及包含受控计量分配功能的气溶胶分配阀,其中保持下一个雾化剂量的计量室(7)与储存器(3)流体连通,允许均匀混合 将要分配的下一个雾化剂量。

    WATER SOLUBLE CAMPTOTHECIN DERIVATIVES
    14.
    发明申请
    WATER SOLUBLE CAMPTOTHECIN DERIVATIVES 审中-公开
    水溶性胶体衍生物

    公开(公告)号:WO1994011377A2

    公开(公告)日:1994-05-26

    申请号:PCT/US1993010987

    申请日:1993-11-10

    Inventor: GLAXO INC.

    CPC classification number: C07D317/66 C07D319/18

    Abstract: The present invention relates to water soluble, camptothecin derivatives of formula (I), wherein A represents a moiety of formula (IIA), (IIB) or (IIC), X is selected from the group consisting of alkyl, aryl, (CH2)mOR , (CH2)mSR and (CH2)mNR R wherein m is an integer of 0 to 6, and R and R are hydrogen, lower alkyl, aryl or together with the nitrogen form a 5-7 membered ring; q is an integer of 0 to 2; n represents the integer 1 or 2; p is an integer of 1 to 6; Y and W are selected from the group consisting of alkyl, aryl, alkoxy, aryloxy and amino, Q is oxygen or sulfur; P is phosphorus; J represents the atoms necessary to complete a 5 or 6 membered aromatic ring; and the pharmaceutically acceptable salts thereof; their use as topoisomerase inhibitors, their preparation; and their use in the treatment of cancer.

    Abstract translation: 本发明涉及式(I)的水溶性喜树碱衍生物,其中A表示式(IIA),(IIB)或(IIC)的部分,X选自烷基,芳基,(CH 2) mOR 1,(CH2)mSR 1和(CH2)mNR 1 R 2其中m是0-6的整数,R 1和R 2是氢,低级烷基, 芳基或与氮一起形成5-7元环; q为0〜2的整数; n表示整数1或2; p为1〜6的整数。 Y和W选自烷基,芳基,烷氧基,芳氧基和氨基,Q是氧或硫; 磷是磷; J表示完成5或6元芳环所必需的原子; 及其药学上可接受的盐; 它们用作拓扑异构酶抑制剂,它们的制备; 并用于治疗癌症。

    DOSAGE INHALATOR PROVIDING OPTIMIZED COMPOUND INHALATION TRAJECTORY
    15.
    发明申请
    DOSAGE INHALATOR PROVIDING OPTIMIZED COMPOUND INHALATION TRAJECTORY 审中-公开
    剂量吸入器提供优化的化合物吸入途径

    公开(公告)号:WO1994004210A1

    公开(公告)日:1994-03-03

    申请号:PCT/US1993007312

    申请日:1993-08-04

    Inventor: GLAXO INC.

    CPC classification number: A61M15/0065 A61M2202/064

    Abstract: A breath actuated dry powder medicament inhaler (10) has a primary air passageway (14) therethrough defining a venturi (14c) in the medial portion thereof. A second air passageway (16) is provided which contains a compound deaggregating swirl chamber (16c) and is fluidly connected to the venturi (14c). A dry powder storage chamber (18) and cooperatively associated metering plate (18b) act to introduce a predetermined amount of compound into the swirl chamber upon actuation of the metering plate. The primary air passageway (14) is configured within the inhalator apparatus so as to create an optimized air flow trajectory through the mouth of the user to minimize dry powder compound impingement upon the outside radius of the throat.

    Abstract translation: 呼吸致动的干粉药物吸入器(10)具有穿过其中间部分限定文丘里管(14c)的一次空气通路(14)。 提供了第二空气通道(16),其包含复合解聚涡旋室(16c)并且流体地连接到文丘里管(14c)。 干粉存储室(18)和配合关联的计量板(18b)用于在计量板致动时将预定量的化合物引入涡流室。 主空气通道(14)构造在吸入器装置内,以便通过使用者的口产生优化的空气流动轨迹,以使干粉混合物撞击在喉部的外半径上。

    SUBSTITUTED PHENYL-1,3 DIOXOLOQUINOLINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS
    16.
    发明申请
    SUBSTITUTED PHENYL-1,3 DIOXOLOQUINOLINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS 审中-公开
    取代的苯基-1,3-二氧杂环戊烷衍生物及其作为抗菌剂的用途

    公开(公告)号:WO1992012981A1

    公开(公告)日:1992-08-06

    申请号:PCT/US1992000581

    申请日:1992-01-24

    Applicant: GLAXO INC.

    CPC classification number: C07D491/04

    Abstract: The present invention relates to the compounds of formula (I), wherein: R1 is hydrogen, hydroxy or amino; R2 is hydrogen, hydroxy, methoxy or methoxymethoxy; R3 is hydrogen, hydroxy, amino, methoxy, methoxymethoxy or, taken together with R2, methylenedioxy (also known as 1,3 dioxolo); R4 is hydrogen, hydroxy, methoxy, methoxymethoxy, benzyl, di(C¿1-4?)alkylaminomethyl or, taken together with R?3¿, methylenedioxy; R5 is hydrogen or hydroxy; provided that at least one of R1 through R5 is other than hydrogen; and i) X2 is hydroxy or methoxy with X?1, X3 and X4¿ being hydrogen or ii) X1 taken together with X2, X2 taken together with X3 or X3 taken together with X4, is methylenedioxy, provided that each of the remaining respective X?1, X2, X3 and X4¿ substituents are hydrogen, intermediates in the synthesis of them, pharmaceutical formulation containing them, their use as inhibitors of topoisomerase and their use in the treatment of tumors.

Patent Agency Ranking